DOWNLOAD CENTER - Speakers Biography
Speakers BiographyProgramme BookISAM - In Brief


Robert Ali 

Associate Professor Robert Ali is a Public Health Physician and Addiction Medicine specialist who has worked in the drug and alcohol field since 1985. He is currently the Director of Community-Based Treatment Interventions at the Drug & Alcohol Services of South Australia and is also the Director of a World Health Organization Collaborating Centre for research into the treatment of drug and alcohol problems based at Adelaide University. He is a member of the Cochrane Alcohol and Drug Group editorial board and a member of the Australian National Council on Drugs executive, the principle advisory group to the Prime Minister. Robert is a member of the WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems. He was the Chair of the National Expert Advisory Committee on Illicit Drugs in Australia from 1998-2004 and President of the Australasian Chapter of Addiction Medicine (Royal Australasian College of Physicians) from 2004-2007. Currently he is the Director of Community-Based Treatment Interventions, Drug & Alcohol Services, South Australia, Australia.

Apinun Aramrattana 

Apinun Aramrattana is a medical epidemiologist and drug use researcher in Thailand.  He is an Assistant Professor of Family Medicine and head of the Center for Substance Abuse Research, Research Institute of Health Sciences at Chiang Mai University, northern Thailand. He is the Thailand Principal Investigator on a number of NIH-supported HIV prevention trials among injection drug users and methamphetamine using youth. He is also an investigator on the network scale-up study for estimating size of injection drug users in Thailand. Dr. Apinun has been one of the principal researchers who organized the first national household surveys of drug use in Thailand supported by the Office of Narcotics Control Board (ONCB). He is now a chairman of a consortium of substance abuse researchers in Thailand. The consortium is working closely with ONCB on developing proper drug surveillance systems at provincial and national levels. He facilitated the development of Yaba (methamphetamine tablet) profile monitoring system now operated for the whole nation. He recently involves in a qualitative study on methamphetamine injection practice in Bangkok and Chiang Mai. His main focuses in recent years have been on improving drug treatment and care system under the justice system as well as developing community-based intervention programs in northern Thailand.

Eliot L. Gardner

Dr. Gardner received his undergraduate training at Harvard College and Harvard Medical School, and pursued graduate studies in neuroscience and psychopharmacology at McGill University and the Montreal Neurological Institute.  After leaving Montreal, Dr. Gardner entered the U.S. Air Force as a medical research officer, serving as a Branch Chief at the U.S. Air Force School of Aerospace Medicine.  In 1969, he became a Postdoctoral Fellow in Neurology and Pharmacology at the Albert Einstein College of Medicine in New York City.  He remained there for 30 years, rising in rank to Professor of Neuroscience, Professor of Psychiatry and Behavioral Sciences, Director of Basic Research in Psychiatry, Director (and founder) of the Research Residency Training Program in Psychiatry, and Co-Director (and co-founder) of the Addiction Medicine Fellowship Program.  In 2000, Dr. Gardner joined the Intramural Research Program of the National Institute on Drug Abuse (NIDA), U.S. National Institutes of Health (NIH), as a Senior Investigator. In 2003, he was appointed Chief of the Neuropsychopharmacology Research Section at NIDA. He is the author of more than 400 journal articles, book chapters, or abstracts in neuroscience and addiction medicine.  He is a recipient of the prestigious Career Scientist Award of the Health Research Council of New York, was elected a Fellow of the American Psychological Association in 1992 for “outstanding contributions to the field of psychopharmacology,” and elected a Fellow of the APA, Division of Behavioral Neuroscience in 1996 for “outstanding contributions to neuroscience.”  In 1999, Dr. Gardner was awarded the prestigious “Lyon-Voorhees Endowed Distinguished Lectureship in Addiction Medicine” by the University of Colorado Medical School.  In 2000, he was named “Distinguished Basic Science Scholar of the Year” by the American Academy of Addiction Psychiatry. Dr. Gardner’s research focuses on brain mechanisms of addiction and on medication development for the treatment of addiction.

Mohamad Hussain Habil

Professor Dr Mohamad Hussain Habil is senior consultant Addiction Psychiatrist in Malaysia and currently the director of the University of Malaya Centre of Addiction Sciences (UMCAS). He is the past president of the ASEAN Psychiatric Association (2008-2010) and Malaysian Psychiatric Asssociation MPA (2004-2006 and 2008-2010). He started his tertiary education and awarded the MBBS degree at University of Malaya. Then he continued his study in professional degree in Master in Psychological Medicine at the same University and subsequently completed his diploma in Addiction Psychiatry at University of London, United Kingdom. Professor Hussain contributes major roles in strategizing and implementing policy of addiction treatment services and training program of addiction fields among health professionals in Malaysia. He is responsible for success story of harm reduction in Malaysia against drugs and HIV problems in Malaysia. He has published numerous papers and books locally and internationally.

Adeeba Kamarulzaman

Adeeba Kamarulzaman is presently a Professor of Medicine and Infectious Diseases and Dean of the Faculty of Medicine at the University of Malaya in Kuala Lumpur Malaysia. She has been at the forefront of Malaysia’s HIV response in both its prevention and treatment programmes. Through the Centre of Excellence of Research in AIDS which she established at the University of Malaya, she directs and oversees a multidisciplinary research program in HIV prevention and treatment.

In addition to her clinical and academic commitments, she has been actively involved in the community response to HIV/AIDS in Malaysia and was instrumental in initiating the Malaysian government’s shift in drug policies which saw the introduction of harm reduction programs in 2005.

Dr. Kamarulzaman is a committee member of numerous regional and international organizations including TREAT Asia, the United Nations Regional Task Force on HIV Prevention Amongst Drug Users and the United Nations Reference Group on HIV and Injecting Drug Use. She is an Executive Committee Member of the International Society of Infectious Diseases and Co-Chairs the WHO Strategic and Technical Advisory Group on HIV and the Antiretroviral Treatment Guidelines. She was recently elected onto the IAS Governing Council and in 2013 Dr Kamarulzaman will host the VIIth IAS HIV Treatment and Pathogenesis Conference in Kuala Lumpur.

Icro Maremmani

Icro Maremmani graduated at the Medical School of the University of Pisa, Italy, in 1979, and went on to specialize in Psychiatry, taking his second degree cum laude, in 1983. He is currently on the Board of Directors of the Department of Psychiatry, at the Santa Chiara Hospital of the University of Pisa, Italy. 

He is Professor of Drug Addiction Medicine at the School of Psychiatry of the University of Pisa. 

He has been President of the European Opiate Addiction Treatment Association (EUROPAD) since its foundation in Geneva (Switzerland) in 1994. As President of EUROPAD he has organized international symposia in the USA, during the Conferences of the American Association for the Treatment of Opiate Dependence (AATOD), and Conferences in several European cities (Saint-Tropez, 1995; Ljubljana, 1997; Arezzo 2000; Oslo 2002; Paris, 2004; Bratislava, 2006; Sofia, 2008; Zagabria, 2010; Barcelona, 2012). 

He received the Dole-Nyswander Award in Washington (DC), USA, in 1994; he was the first non-American winner of that award. In 2004 he received the “Chimera Award”, in Paris. In 1990 (Cagliari, Italy) he became a founding member of the Società Italiana Tossicodipendenze - Italian Society of Addiction Medicine (SITD-ItSAM), and is currently its President. 

He is President of the World Federation for the Treatment of Opioid Dependence (WFTOD), an NGO with Special Consultative Status with Economic and Social Council (ECOSOC), since 2011.

Alex Wodak

Dr Alex Wodak AM is a physician and was Director of the Alcohol and Drug Service at St Vincent’s Hospital in Sydney from 1982 until 2012. With colleagues he established the first needle syringe program and the first medically supervised injecting centre in Australia when both were pre-legal. He was the foundation President of the International Harm Reduction Association (1996-2004) and is the current President of the Australian Drug Law Reform Foundation. Dr Wodak has published about 300 scientific papers in the alcohol and drug field. He helped establish the National Drug and Alcohol Research Centre (NDARC), the Australian Society of HIV Medicine (ASHM) and the NSW Users AIDS Association (NUAA).  Dr Wodak has been involved in HIV prevention among and from people who inject drugs in countries in West, Central, South, Southeast and East Asia. Since retiring in 2012 he has focused on drug law reform.

Nicholas Lintzeris 

Associate Prof Nicholas Lintzeris is the Director of the Drug and Alcohol Services, South Eastern Sydney and he is also the Chief Addiction Medicine Specialist at the Mental Health Drug & Alcohol Office, New South Wales Ministry of Health

Hannu Alho  

Current positions:
  • Professor of Addiction Medicine, Institute of Clinical Medicine, University of Helsinki, Finland 
  • Research Professor, Department of Mental Health and Substance Abuse, National Institute of Health and Welfare, Helsinki
  • Chief  Physician, Department of Alcohol Abuse, Helsinki University Hospital

Main interests, clinical research on pharmacological treatment of alcoholism, prevention of alcohol related health problems, treatment of pathological gambling and treatment opiate addictions. Professor Alho’s research team was one of the first to demonstrate that targeted (as needed) opiate antagonist treatment naltrexone is effective in reducing alcohol consumption and since has been active in the development and testing of related treatments.


211 original articles (186 PubMed listed), several publications and books on Teaching and Addiction Medicine in Finnish. 

Current Position of Trusts:
  • President of International Society for Addiction Medicine (ISAM). 
  • Immediate Past Chairman of the Finnish Society of Addiction Medicine 
  • Past Chairman of the Finnish Society of Alcohol and Drug Research

Nady el-Guebaly 

Dr. el-Guebaly is Professor and Head, Division of Addiction, Department of Psychiatry at the University of Calgary and past Chair of the Department. He is the Founding Past Medical Director of the Calgary Health Region’s Addiction Program and Founding Past President of the International Society of Addiction Medicine. Currently, he is the Research Director of the Alberta Gaming Research Institute; Chief Examiner of the International Society of Addiction Medicine; Editor-in-Chief, Canadian Journal of Addiction. Major research interests have resulted in 250 peer-reviewed papers and chapters and 60 past and current research grants.

Michael Farrell  

Professor Michael Farrell, is the Director of the National Drug and Alcohol Research Centre in UNSW, Sydney New South Wales since March 2011. He was a Professor of Addiction Psychiatry at the Institute of Psychiatry, Kings College London before moving to Sydney.

His area of interests have been broad based population studies based on the UK National Psychiatric Morbidity Programme where the issues of substance use and psychiatric morbidity were explored. He is also interested in Evidence Based Practice and Treatment Evaluation and the Translation of new evidence into practice. He has researched aspects of drugs and prison and particularly the risks of overdose on leaving prison or other closed institutions. He is a founding Editor of the Cochrane Drug and Alcohol Group.

 He has published over 200 scientific papers and is a member of the WHO Expert Committee on Drug Dependence. He chaired the Scientific Advisory Committee of the European Monitoring Centre for Drugs and Drug Addiction. He has undertaken a wide range of work for international agencies and for National Governments on aspects of National Drug Policies.

Gabriele Fischer   

Professor Gabriele Fischer is currently working at the Medical University of Vienna Center for Public Health Department of Psychiatry & Psychotherapy Währinger Gürtel 18-20, 1090 Vienna, Austria. She is a members for various scientific or advisory board; Scientific or Advisory Board Member of Austrian Medical Council Scientific advisory board: Addiction and ADHD Scientific advisory board of Quality control and Quality management in Austria, EUFAS European Federation of Addiction Societies, WPA Section on Dual Disorders/Pathology, advisory board member for EU framework grants UNODOC technical consultant. Development on guidelines for the diagnoses and treatment of pregnant substance depending women

Linda Gowing  

Dr Linda Gowing is a Principal Research Officer with Drug and Alcohol Services South Australia, and an Associate Professor in the Discipline of Pharmacology at the University of Adelaide. Linda has an honours degree in clinical biochemistry, and a PhD in experimental pathology. After 11 years in the Australian Federal Department of Health, Dr Gowing moved to DASSA in 1998 to develop evidence-based practice work in the organisation.

Dr Gowing has substantial experience in the preparation of systematic reviews, including Cochrane reviews, and evidence-based guidelines. She is the primary author of five Cochrane reviews, four on approaches to the management of opioid withdrawal, and one on substitution treatment of opioid dependence for prevention of HIV. Dr Gowing has been a mentor for researchers in Thailand, China, USA and Australia, helping them to become familiar with the systematic review process and undertake their own Cochrane reviews on the treatment of alcohol and other drug use, and is an author on three Cochrane reviews that are currently in preparation.

Dr Gowing is a member of the editorial board for the Cochrane Drugs and Alcohol Group, an Assistant Editor for the journal Addiction, and teaches research methods for the International Program on Addiction Studies which is offered on-line by the University of Adelaide, Virginia Commonwealth University and Kings College in London (UK) in collaboration.

Sung-Gon, Kim  

Current appointment:

Department of Psychiatry, School of Medicine
Pusan National University  


  • 1979-84 - M.D. Pusan National University (PNU)
  • 1989-90 - M.Sc. PNU, Psychiatry
  • 1996-98- Ph.D. PNU, Psychiatry                             

Postgraduate Training and Fellowship Appointments:

  • 1999-2000
    Visiting Assistant Professor, Psychiatry
    University of Pennsylvania

Faculty appointments:

  • 1992-1993  Chairman, Psychiatry, Bongsaeng Memorial Hospital
  • 2001-2006  Associate Professor, Psychiatry, PNU
  • 2006-present  Professor, Psychiatry, PNU                                               

Hospital and Administrative Appointments:

  • 1994-1999Director, Resident Training, PNUH
  • 1995-2008Chief, Alcohol and Drug Use Clinic, PNUH
  • 2002-presentChief, Pusan Alcohol Counseling Center, Pusan
  • 2004-2006Chief, Public Relations, PNUH
  • 2008-2010Director, Clinical Research Center
    Pusan National University Yangsan Hospital (PNUYH)
  • 2008-presentChief, Psychiatry, PNUYH
  • 2013-presentChairman, Psychiatry, PNU

  Memberships in Professional and Scientific Societies:

  • Korean Neuropsychiatric Association (Member)
  • Korean Academy of Addiction Psychiatry (Member)  (Previous President, 2010-2012)
  • Judgment Committee of Treatment for Drug-related Criminals in Pusan (Member)
  •  Research Society on Alcoholism (Member)
  • Addiction Society of Busan and Kyeongsang-namdo (President)
  • Management Center for Health Promotion in Pusan (Member)
  • International Society for Biomedical Research on Alcoholism (Member)
  • Asia-Pacific Society for Alcohol and Addiction Research (Member, Board of Directors)
  • International Society of Addiction Medicine (Member)

  Editorial Positions:

  • Editorial Board, Journal of Korean Academy of Addiction Psychiatry
  • Review Committee, Korean Journal of Biological Psychiatry
  • Editorial Board, Psychiatric Investigation
  • Board of Field Editor for ‘ACER’
  • Editorial Advisory Board of ‘Addiction Genetics’

Research Publications:  62 papers

Walter Ling   

Professor Walter Ling is Professor of Psychiatry and Founding Director of Integrated Substance Abuse Programs (ISAP) at UCLA, one of the foremost substance abuse research groups in the US and worldwide. He is board certified in neurology and psychiatry, is active in research and clinical work. His current research includes medication development clinical trials for treatment of cocaine and methamphetamine dependence, prescription opiate dependence, opiate induced hyperalgesia, treatment of pain in opiate-maintained patients, including those treated with buprenorphine, and the role of buprenorphine in the management of pain in these patients. He is a member of the Editorial Board of the Cochrane Drug and Alcohol Review Group and he has been an advocate for promoting more cost-effective addiction treatment by adopting evidence-based practice using Cochrane reviews.

       Contact Us: isam2013kl@gmail.com      Find-us-on-facebook_logo.jpg

National Anti Drug Agency, Malaysia
of Health, Malaysia
Malaysian AIDS Council

of Prison, Malaysia
Supported by